Advanced search
Start date
Betweenand

Imune-sensors for detection of prostate circulating tumor cells using murine monoclonal antibodies

Grant number: 18/19083-7
Support type:Regular Research Grants
Duration: February 01, 2019 - July 31, 2021
Field of knowledge:Biological Sciences - Morphology - Histology
Principal Investigator:Andrei Moroz
Grantee:Andrei Moroz
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Assoc. researchers:Ana Marisa Fusco Almeida ; Elenice Deffune ; Guilherme Peixoto ; Marcel Otavio Cerri ; Ramon Kaneno ; Sidney José Lima Ribeiro ; Wagner José Fávaro
Associated scholarship(s):19/00356-6 - Technical training in animal cell culture and hybridoma technology, BP.TT

Abstract

Prostate cancer (PCa) is the most diagnosed cancer and the second cause of cancer related deaths among men in America and in Western European countries. In Brazil, the number of new cases of PCa estimated for 2018 was 68,220, with an average survival of 24 months in patients who develop the most lethal form of PCa. Its early detection is of fundamental importance and, for this, monoclonal antibodies are perfect tools, with an important role in the therapy, diagnosis and staging of the disease. However, classical techniques for obtaining monoclonal antibodies may not be able to select or increase the probability of obtaining antigen-specific antibodies that are directly related to tumor metastasis processes. In this context, this project proposes to use a novel technique, called multiple tolerization subtractive immunization (MTSI), developed at my laboratory, which helps selecting highly aggressive and/or rarely expressed antigens on the surface of tumor cells. The two best antibodies, once produced and characterized, will be used as candidates on a diagnostic platform using the technology of immunosensors, based on nanostructured fibroin films, and also in immunohistochemistry. These sensors may help in the clinical management of this disease, when detecting and characterizing circulating tumor cells, facilitating a quick diagnosis of recurrence or metastasis. (AU)